Takeda Pharmaceutical has a total of 37944 patents globally, out of which 13310 have been granted. Of these 37944 patents, more than 58% patents are active. United States of America is where Takeda Pharmaceutical has filed the maximum number of patents, followed by Japan and Europe and it also seems reasonable as the biggest market for Takeda Pharmaceutical is USA, it has generated an annual revenue of $30.05 billion in the year 2021. USA seems to be the main focused R&D center and Japan is the origin country of Takeda Pharmaceutical.
Takeda Pharmaceutical was founded in the year 1781 by Chobei Takeda. Company is doing business in manufacturing drugs, and is one of the 20 largest pharmaceutical companies in the world. As of December 2021, Takeda Pharmaceutical has a market cap of $43.74 Billion.
Do read about some of the most popular patents of Takeda Pharmaceutical which have been covered by us in this article and also you can find Takeda Pharmaceutical’s patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Takeda Pharmaceutical’s patent portfolio.
How many patents does Takeda Pharmaceutical have?
Takeda Pharmaceutical has a total of 37944 patents globally. These patents belong to 9174 unique patent families. Out of 37944 patents, 22041 patents are active.
How many Takeda Pharmaceutical patents are Alive/Dead?
Worldwide Patents
Patent Families
How Many Patents did Takeda Pharmaceutical File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Takeda Pharmaceutical Applications Filed | Takeda Pharmaceutical Patents Granted |
| 2011 | 2134 | 856 |
| 2012 | 1925 | 971 |
| 2013 | 1690 | 1015 |
| 2014 | 1882 | 1027 |
| 2015 | 1594 | 906 |
| 2016 | 1179 | 934 |
| 2017 | 1218 | 1016 |
| 2018 | 1209 | 995 |
| 2019 | 1078 | 1004 |
| 2020 | 643 | 865 |
| 2021 | 283 | 701 |
Which Takeda Pharmaceutical Drug Patents are Expiring in the Next 10 Years?
The patent no. US9974835B2 which is expiring in May, 2026, describes the Study for improvement of intestinal absorption in short bowel syndrome patients with a colon by using a GLP-2 receptor agonist, like teduglutide.
Given below is the list of few drugs patented by Takeda Pharmaceutical accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.
| Drug Name | Patent Number | Patent Title | Patent Expiration |
| Gattex Kit | US9974835B2 | Treatment Of Short Bowel Syndrome… | May, 2026 |
| Trintellix | US9278096B2 | Therapeutic Uses Of Compounds Having… | Mar, 2032 |
| Colcrys | US8440721B2 | Methods For Concomitant Admin… | Feb, 2029 |
| Dexilant | US8871273B2 | Method For Producing Granules | Jan, 2028 |
| Ninlaro | US8871745B2 | Proteasome Inhibitors | Aug, 2027 |
Interested in knowing about Takeda Pharmaceutical’s Drug Patents Expiring in the next 10 years?
How Many Patents did Takeda Pharmaceutical File in Different Countries?
Countries in which Takeda Pharmaceutical Filed Patents
| Country | Patents |
| United States Of America | 5144 |
| Japan | 3512 |
| Europe | 2955 |
| Australia | 2666 |
| Canada | 1688 |
| China | 1374 |
| Korea (South) | 1055 |
| Hong Kong (S.A.R.) | 922 |
| Mexico | 863 |
| India | 793 |
| Brazil | 770 |
| Israel | 724 |
| Singapore | 686 |
| Taiwan | 681 |
| Spain | 680 |
| Argentina | 518 |
| Eurasia | 464 |
| South Africa | 436 |
| New Zealand | 436 |
| Peru | 420 |
| Denmark | 412 |
| Poland | 370 |
| Germany | 361 |
| Turkey | 338 |
| Austria | 332 |
| Portugal | 327 |
| Thailand | 307 |
| Vietnam | 306 |
| Philippines | 277 |
| Norway | 274 |
| Malaysia | 272 |
| Chile | 264 |
| Colombia | 247 |
| Slovenia | 246 |
| Russia | 232 |
| Morocco | 225 |
| Croatia | 219 |
| United Kingdom | 211 |
| Costa Rica | 208 |
| Indonesia | 195 |
| Cyprus | 184 |
| Hungary | 179 |
| Dominican Republic | 177 |
| Ukraine | 171 |
| Ecuador | 169 |
| Serbia | 158 |
| Uruguay | 156 |
| Tunisia | 135 |
| Georgia | 124 |
| Lithuania | 87 |
| Montenegro | 64 |
| Africa | 69 |
| Jordan | 39 |
| Iceland | 39 |
| Gulf Cooperation Council | 37 |
| Czech Republic | 33 |
| Slovakia | 27 |
| San Marino | 21 |
| Kazakhstan | 17 |
| Nicaragua | 15 |
| Belarus | 13 |
| Cuba | 13 |
| Guatemala | 12 |
| Estonia | 12 |
| Netherlands | 11 |
| Bulgaria | 10 |
| Luxembourg | 8 |
| Saudi Arabia | 8 |
| Honduras | 6 |
| Finland | 5 |
| El Salvador | 3 |
| Panama | 3 |
| Belgium | 2 |
| Mongolia | 2 |
| France | 1 |
| Algeria | 1 |
| Sweden | 1 |
| Republic of Moldova | 1 |
| Egypt | 1 |
| Italy | 1 |
Where are Research Centers of Takeda Pharmaceutical Patents Located?
10 Best Takeda Pharmaceutical Patents
US20030092019A1 is the most popular patent in the Takeda Pharmaceutical portfolio. It has received 372 citations so far from companies like Medtronic, Metamorphix and Applera Corporation.
Below is the list of 10 most cited patents of Takeda Pharmaceutical:
| Publication Number | Citation Count |
| US20030092019A1 | 372 |
| US20100324936A1 | 274 |
| US20030186374A1 | 252 |
| US6913768B2 | 206 |
| WO2011022439A1 | 201 |
| WO2005095381A1 | 197 |
| WO2004041201A2 | 190 |
| WO2009143389A1 | 188 |
| WO2003099773A1 | 183 |
| JP2003519698A | 182 |
Which Companies are using Takeda Pharmaceutical Patents to Advance their Research?
If patents or patents from a particular technology area of a company receive a lot of citations, it implies that the technology is being followed and incrementally innovated by the citing companies. It also indicates that citing companies are working on similar and closely related technologies.
The top citing companies in the Takeda Pharmaceutical patent portfolio are Baxalta, Shire and National Institutes Of Health.
List of the top forward citing Companies –
| Company | Number of Patents |
| Baxalta | 64 |
| Shire | 44 |
| National Institutes Of Health | 43 |
| Weatherford | 28 |
| Translate Bio | 25 |
| Novartis | 20 |
| Halliburton | 17 |
| Life Technologies | 16 |
| Kempharm | 13 |
| Apple | 12 |
Count of 102 and 103 Type Rejections based on Takeda Pharmaceutical Patents
Top Takeda Pharmaceutical Patents used in Rejecting Most Patent Applications
| Patent Number | Count of Rejected Applications |
| US20100324936A1 | 39 |
| US7836973B2 | 35 |
| US7384783B2 | 28 |
| US8050461B2 | 19 |
| US20110244026A1 | 17 |
| US8304524B2 | 15 |
| US8603805B2 | 14 |
| US8546548B2 | 14 |
| US8193182B2 | 14 |
| US8390821B2 | 13 |
What Percentage of Takeda Pharmaceutical US Patent Applications were Granted?
Takeda Pharmaceutical (Excluding its subsidiaries) has filed 2142 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 1473 have been granted leading to a grant rate of 73.58%.
Below are the key stats of Takeda Pharmaceutical patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Takeda Pharmaceutical?
| Law Firm | Total Application | Success Rate |
| Wenderoth Lind & Ponack L L P | 280 | 71.74% |
| Foley & Lardner Llp | 229 | 71.08% |
| Mintz Levin Special Group | 186 | 60.89% |
| Takeda California Inc | 158 | 68.61% |
| Morgan Lewis & Bockius Llp Sf Baxter | 135 | 91.67% |
| Takeda Pharmaceuticals North America Inc | 133 | 63.16% |
| Troutman Pepper Hamilton Sanders Llp | 101 | 97.80% |
| Hamre Schumann Mueller & Larson P C | 97 | 64.95% |
| Locke Lord Llp | 88 | 59.09% |
| Foley & Lardner | 82 | 98.78% |
“Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine.”
Takeda Pharmaceutical R&D is on a never-ending quest for scientific breakthroughs in order to bring transformative therapies to patients all over the world. This necessitates a large network of experts, unparalleled knowledge in its primary treatment areas, and world-class resources. Takeda is cultivating an ecosystem of innovation to integrate cutting-edge science into significant health solutions through collaborations, collaboration, and research.
Takeda Pharmaceutical is focusing on therapeutic areas where it wants to be at the forefront of innovation: oncology, gastroenterology (GI), and central nervous system (CNS) disease areas where there is a high level of patient need, where it can leverage its deep scientific expertise, where it has a strong track record of recent successes, and where it plans to continue discovering innovative new medicines. Takeda’s global health strategy to vaccines, which was predicated on its dengue and norovirus initiatives, is being expanded.
EXCLUSIVE INSIGHTS COMING SOON!
What are Takeda Pharmaceutical key innovation segments?
What Technologies are Covered by Takeda Pharmaceutical?
The chart below distributes patents filed by Takeda Pharmaceutical in different countries on the basis of the technology protected in patents. It also represents the markets where Takeda Pharmaceutical thinks it’s important to protect particular technology inventions.
R&D Focus: How Takeda Pharmaceutical search focus changed over the years?
EXCLUSIVE INSIGHTS COMING SOON!
Interested in knowing about the areas of innovation that are being protected by Takeda Pharmaceutical?